- The High Court has taken decisive action to stem the tide of escalating medicine prices nationwide, issuing directives to ensure effective measures are in place. Under the court’s order, the Director General of the Directorate General of Drug Administration, along with other relevant stakeholders, has been tasked with implementing strategies to curb medicine price hikes. Additionally, the court has issued a rule requiring concerned authorities to provide explanations for their failure to address the surge in medicine prices, potentially facing legal consequences for their inaction. Furthermore, the High Court has mandated the cessation of sales for unapproved drugs imported from overseas, emphasizing the importance of regulatory compliance in safeguarding public health. The ruling, delivered by the High Court bench comprising Justice Mustafa Zaman Islam and Justice Md Atabullah, follows a writ petition filed in response to alarming reports of medicine price hikes. The petition, lodged by the Consumer Association of Bangladesh (CAB), cited a news report revealing a staggering surge in medicine prices ranging from 7% to 140% within a mere two-week period. According to the petition, various pharmaceutical companies have indiscriminately increased prices for their products over the past two months, resulting in significant financial burdens for consumers. Reports indicate that prices for approximately 50 different types of medicines have witnessed hikes ranging from 20% to 140%, highlighting the urgent need for regulatory intervention to safeguard consumer interests and ensure equitable access to essential healthcare products.